Nonetheless, we conclude that “De novo replication repair deficient glioblastoma, IDH-wildtype” represents a biologically distinct subtype in the adult population that will benefit from prospective identification and unique treatment, potentially including immune checkpoint blockade. This evidence concerns the gene IDH1 and glioblastoma.